Innovation is of no worth if it doesn’t provide better outcomes for patients. Indeed, such advancements should hold as centre the amelioration of the overall patient experience.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.